- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03850106
Effects of INDUS810 on Body Composition, Muscular Performance, and Training Adaptations
Effects of INDUS810 on Body Composition, Muscular Performance, and Training Adaptations During 12-weeks of Supplementation and Concurrent Training
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This 12-week study is a randomized, parallel-group, placebo-controlled, clinical trial of N=66 recreationally, but normal to moderately overweight/obese male subjects to be recruited at a single investigational center in Northeast Ohio (i.e. The Center for Applied Health Sciences).
Subjects will attend 4 study visits. At Visit 1, subjects will be screened for participation (i.e., medical history, physical exam, routine blood work, background baseline diet). At Visits 2 (day 0 - Baseline Testing), and 4 (week 12), measurements of various hemodynamic, hematologic & biochemical biomarkers of safety (Total testosterone, CBC, and comprehensive metabolic panel) will be made. At Visits 2, 3, and 4, the following efficacy measures will be obtained: Body Composition assessment via DEXA, Upper and Lower Body Performance testing on a Smith Machine and a TENDO unit utilizing the bench press and squat exercises, and anchored 100mm VAS scales (for various psychometric indices). In addition, a comprehensive side effect profile/ adverse event monitoring will take place throughout the 12-week study duration.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Stow, Ohio, United States, 44224
- The Center for Applied Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provide voluntary signed and dated informed consent.
- Be in good health as determined by medical history and routine blood chemistries.
- Age between the ages of 18 and 45.
Body Mass Index (BMI):
- 22-25; Waist:Hip Ratio 0.9-1
- 25-35; Waist:Hip Ratio 0.85-1
- Normotensive (supine, resting systolic blood pressure <140 mm Hg and diastolic blood pressure < 90 mm Hg. If the first measurement is slightly elevated above these limits, the subject will be given a brief (5 minute) rest period, and two more measurements will be taken. The average of all three measurements will be used to determine eligibility.
- Normal supine, resting heart rate (<90 per minute).
- Willing to duplicate their previous 24-hour diet, and fast for 8-10 hours prior each of the treatments.
- Has been participating in regular exercise training, at least 3 days per week, for the past 1-2 months.
Exclusion Criteria:
- History of diabetes.
- Use of any pre-workout or creatine containing products in the last 4 weeks.
- History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).
- Prior gastrointestinal bypass surgery (Lapband, etc.).
- Other known gastrointestinal or metabolic diseases that might impact absorption or amino acid metabolism, e.g. short bowel syndrome, diarrheal illnesses, history of colon resection, gastro paresis, Inborn-Errors-of-Metabolism (such as PKU).
- Chronic inflammatory condition or disease (e.g. rheumatoid arthritis, Crohn's disease, ulcerative colitis, Lupus, HIV/AIDS, etc.). -Known sensitivity to any ingredient in the test formulations as listed in the Certificates- of-Analysis.
- Currently participating in another research study with an investigational product or have been in another research study in the past 30 days.
- Concomitant use of corticosteroids or testosterone replacement therapy (ingestion, injection, or transdermal).
- Any other diseases or conditions that, in the opinion of the medical staff, could confound the primary endpoint or place the subject at increased risk of harm if they were to participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo (microcrystalline cellulose)
|
Placebo
|
Active Comparator: Indus810
Indus810 ( 500mg/d)
|
Active product
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body composition
Time Frame: Change in score from Day 0 to day 56 and from day 0 to day 84
|
body fat percentage (%)
|
Change in score from Day 0 to day 56 and from day 0 to day 84
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Upper body strength
Time Frame: Change in pounds from Day 0 to day 56 and from day 0 to day 84
|
Weight lifted in pounds
|
Change in pounds from Day 0 to day 56 and from day 0 to day 84
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Tim N Ziegenfuss, PhD, The Center for Applied Health Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INDUS-PC-BC-2018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Weakness, Muscle
-
St. Luke's-Roosevelt Hospital CenterCompletedFall Risk | Quadriceps Muscle Weakness | Adductor Muscle WeaknessUnited States
-
University of Central ArkansasCompletedPelvic Floor Muscle WeaknessUnited States
-
Association Pro-arteActive, not recruitingWeakness, Muscle | AmyotrophiaFrance
-
Ludwig Boltzmann Institute of Electrical Stimulation...Medical University of Vienna; European Union; Comenius University; Ministry of...CompletedMuscle Weakness Condition | Therapy EffectAustria, Slovakia
-
Rutgers, The State University of New JerseyRecruitingPhysical Disability | Muscle Atrophy or Weakness | Muscle Loss | Physical Inactivity | Delirium in Old Age | Hospital Acquired Condition | Weakness, MuscleUnited States
-
University of MilanCompleted
-
University of Central FloridaCompletedMuscle Weakness | Muscle Atrophy | Muscle Loss | Weakness, Muscle | Injury, KneeUnited States
-
University of Texas Southwestern Medical CenterTerminatedMuscle Cramp | Statin Adverse Reaction | Weakness, Muscle | AcheUnited States
-
Damanhour UniversityCompletedNeuromuscular Electrical Stimulation | ICU Acquired Muscle WeaknessEgypt
-
Riphah International UniversityCompletedMuscle Weakness ConditionPakistan
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy